Roundup: Three Chinese Deals To Put On Your Radar
This article was originally published in PharmAsia News
Executive Summary
The New Year may have just kicked off, but in China it has already seen two acquisitions, one fundraising and over a hundred million dollars in transactions.
You may also be interested in...
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
There were four biopharma IPOs in October – Myovant, Ra, CRISPR and AzurRX – but only one was trading above its offering price by the end of the month, reflecting investor uncertainty about the industry.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.